425: VYNE Therapeutics to Merge with Yarrow Bioscience

VYNE Therapeutics and Yarrow Bioscience announced a definitive merger agreement, creating a combined entity focused on advancing Yarrow's lead program, YB-101, for Graves disease and thyroid eye disease, supported by $200 million in pre-closing financings.

Summary

• VYNE Therapeutics Inc. (VYNE) and Yarrow Bioscience, Inc. (Yarrow) have entered into a definitive merger agreement.
• The combined company will operate as Yarrow Bioscience, Inc. and trade on Nasdaq under the ticker symbol YARW.
• Pre-Merger Yarrow stockholders are expected to own approximately 97% of the combined company, while pre-Merger VYNE stockholders are expected to own approximately 3%.
• The merger is intended to qualify as a tax-free reorganization for federal income tax purposes.
• VYNE expects to declare a cash dividend to its pre-Merger stockholders of approximately $14.5 million to $16.5 million.
• Yarrow has secured approximately $200 million in pre-closing private financings from a syndicate of healthcare investors, including RTW Investments, OrbiMed Advisors, Janus Henderson Investors, venBio Partners, Logos Capital, LifeSci Venture Partners, and Perceptive Advisors.
• The combined company's cash balance at closing is expected to fund operations into 2028.
• The primary focus of the combined company will be advancing YB-101 (also known as GS-098), a clinical-stage, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR), for Graves disease (GD) and thyroid eye disease (TED).
• YB-101 was in-licensed from Changchun GeneScience Pharmaceutical Co., Ltd (GenSci) for global ex-China rights.
• A Phase 1 trial for YB-101 in TED is ongoing in China by GenSci, with data expected in the first half of 2026.
• A combined Phase 1b/2b trial for YB-101 in GD patients in the United States and other territories is planned for the first half of 2026, with Phase 1b data expected in the second half of 2027.
• The merger has been unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2026, subject to stockholder approvals and other customary closing conditions.

Sentiment

Score: 6

Explanation: The merger provides Yarrow with substantial funding ($200 million) and a public listing, enabling the advancement of its lead candidate, YB-101, into later-stage clinical trials with a cash runway into 2028. For VYNE, it represents a strategic pivot and a cash dividend to existing shareholders, but also significant dilution (97% ownership by Yarrow stockholders) and the discontinuation of its prior pipeline. The overall sentiment is cautiously optimistic for the new entity's drug development prospects, but a clear negative for existing VYNE shareholders' ownership stake.

Positives

• Yarrow secured approximately $200 million in pre-closing private financings from a syndicate of industry-leading healthcare investors.
• The combined company's cash balance at closing is expected to fund operations into 2028, supporting clinical advancements.
• YB-101 is a clinical-stage, potentially first-in-class TSHR antibody for Graves disease and thyroid eye disease, addressing significant unmet medical needs.
• YB-101's targeted mechanism of action, selectively blocking TSHR, aims to offer a differentiated risk-benefit profile compared to existing therapies.
• Pre-merger VYNE stockholders will receive a cash dividend of approximately $14.5 million to $16.5 million.
• The combined company will be led by an experienced management team, including Rebecca Frey as CEO and Lori Payton, Ph.D. as Chief Development Officer, with board representation from leading investors.

Negatives

• Pre-merger VYNE stockholders are expected to own only approximately 3% of the combined company, representing significant dilution.
• VYNE's existing BET inhibitor platform and pipeline will be discontinued, with the combined company focusing solely on Yarrow's YB-101.
• VYNE options with an exercise price greater than the Company Closing Price will be cancelled for no consideration.
• A $1,000,000 termination fee is payable by either party under specified circumstances, indicating potential financial risk if the merger fails.

Risks

• Failure to satisfy closing conditions, including timely shareholder approval for the transaction.
• Uncertainties regarding the timing of the consummation of the Merger.
• VYNE's ability to manage its operating expenses and expenses associated with the Merger pending closing.
• Failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Merger.
• Adjustments to the exchange ratio could result in VYNE shareholders and Yarrow stockholders owning more or less of the combined company than currently anticipated.
• Risks related to the market price of VYNE's common stock relative to the value suggested by the exchange ratio.
• Unexpected costs, charges, or expenses resulting from the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger.
• Uncertainties associated with Yarrow's product candidates, as well as risks associated with their clinical development and regulatory approval, including potential delays in trial initiation, enrollment, and completion.
• Inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and preclinical programs.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom.
• Failure to realize any value from product candidates and preclinical programs being developed.
• Failure to realize certain anticipated benefits of the Merger, including with respect to future financial and operating results.
• Risk that the related financing is not consummated.
• Risk that VYNE's shareholders receive more or less of the cash dividend than currently anticipated.
• The outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby.
• The ability of the combined company to obtain, maintain, and protect its intellectual property rights, particularly those related to its product candidates.
• Changes to clinical trial designs and regulatory pathways.
• Competitive responses to the Merger and changes in expected or existing competition.
• Legislative, regulatory, political, and economic developments.

Future Outlook

The combined company, Yarrow Bioscience, Inc., will focus on advancing YB-101, a TSHR antibody for Graves disease and thyroid eye disease. A Phase 1b/2b trial for YB-101 in Graves disease is expected to start in the first half of 2026, with Phase 1b data anticipated in the second half of 2027. A Phase 1 trial for YB-101 in thyroid eye disease is ongoing in China, with data expected in the first half of 2026. The company expects its cash balance to fund operations into 2028, supporting these clinical advancements.

Management Comments

• "We are excited about this merger, which establishes Yarrow on a strong foundation to advance YB-101 for patients living with Graves disease and thyroid eye disease." Rebecca Frey, Pharm.D., President and Chief Executive Officer of Yarrow.
• "Autoimmune thyroid disorders represent areas of significant unmet need, and we believe YB-101 has the potential to deliver meaningful clinical benefit through its highly targeted TSHR-directed mechanism of action." Rebecca Frey, Pharm.D., President and Chief Executive Officer of Yarrow.
• "Together with an exceptional leadership team and the support of a premier group of life sciences investors, Yarrow is well positioned to deliver on our mission to transform treatment options in this field." Rebecca Frey, Pharm.D., President and Chief Executive Officer of Yarrow.
• "We believe this merger provides our stockholders a compelling opportunity to realize both shortand long-term value creation through a cash dividend and the continued advancement of Yarrows potential breakthrough therapies for the treatment of thyroid autoimmune diseases." David Domzalski, President and Chief Executive Officer of VYNE.
• "With this capital and support from world-class investors, we are confident the combined company is well equipped to execute its strategy through significant value-driving clinical catalysts." David Domzalski, President and Chief Executive Officer of VYNE.
• "Our decision to enter into this agreement with Yarrow follows a thorough strategic review and we believe that this transaction positions our stockholders to realize value both in the short term and in the years ahead." David Domzalski, President and Chief Executive Officer of VYNE.
• "At Yarrow, we are driven to develop safe and effective therapies to address unmet needs in thyroid autoimmune diseases, which produce serious, chronic, and debilitating clinical sequelae." Rebecca Frey, Pharm.D., President and Chief Executive Officer of Yarrow.
• "Currently there are no approved therapies that can treat both Graves hyperthyroidism and TED, and we believe that an easy-to-administer TSHR antibody with a favorable risk/benefit profile could become the preferred treatment for patients who are not adequately controlled on first-line therapies." Rebecca Frey, Pharm.D., President and Chief Executive Officer of Yarrow.

Industry Context

The merger positions the combined entity, Yarrow Bioscience, to address significant unmet needs in autoimmune thyroid disorders, specifically Graves disease and thyroid eye disease. The lead candidate, YB-101, is a TSHR antibody, highlighted as a novel and targeted approach. The filing notes that existing IGF-1R directed therapies for TED, such as teprotumumab, have shown clinical benefit but are associated with dose-limiting toxicities (hearing impairment, hyperglycemia) due to broad receptor expression. YB-101's TSHR target has more restricted tissue expression, aiming for a differentiated risk-benefit profile, suggesting a competitive landscape where Yarrow aims to offer a superior or alternative treatment option.

Comparison to Industry Standards

• YB-101 targets the thyroid-stimulating hormone receptor (TSHR), a key disease-driving pathway with more restricted tissue expression.
• Existing IGF-1R-directed therapies for TED, such as teprotumumab, have demonstrated clinical benefit but are associated with dose-limiting toxicities like hearing impairment and hyperglycemia due to their broad receptor expression.
• YB-101's targeted approach aims to address an important unmet need for therapies with differentiated risk-benefit profiles compared to these existing treatments.
• Currently, there are no approved therapies that can treat both Graves hyperthyroidism and TED, suggesting YB-101 could fill a significant gap if successful.

Management Changes

Corporate Governance

Legal Proceedings

• The filing includes general risk disclosures regarding the outcome of any legal proceedings that may be instituted against the combined company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby. No specific pending or threatened legal proceedings are detailed.

Related Party Transactions

• Yarrow Bioscience was founded by RTW Investments, which is also a lead investor in the pre-closing financings, indicating a significant related party relationship.
• OrbiMed Advisors, another lead investor in the pre-closing financings, has a General Partner (Mona Ashiya, Ph.D.) who will join the combined company's board of directors.

Stakeholder Impact

• **VYNE Shareholders**: Will receive a cash dividend of $14.5M-$16.5M but face significant dilution, owning only approximately 3% of the combined company. Their investment focus shifts entirely to Yarrow's pipeline.
• **Yarrow Stockholders**: Will own approximately 97% of the combined company, gaining a public listing and substantial capital for their lead program.
• **VYNE Employees**: Vesting of all options and restricted stock units will accelerate, with in-the-money options cashed out and out-of-the-money options cancelled. Executive leadership will change.
• **Yarrow Employees**: Their leadership team will assume control of the combined company, with new key management appointments.
• **New Investors (Yarrow Financings)**: Provide $200M in capital, gaining significant ownership in the combined public entity focused on YB-101.
• **Patients/Customers**: Potential for new therapeutic options for Graves disease and thyroid eye disease if YB-101 successfully progresses through clinical development.

Next Steps

• VYNE to seek stockholder approval for the issuance of shares, change of control, and a reverse stock split.
• Yarrow to seek stockholder approval for the Merger Agreement.
• VYNE to prepare and file a Registration Statement on Form S-4 with the SEC.
• Nasdaq approval for the listing application of the combined company.
• Closing of the Merger, expected in the second quarter of 2026.
• The combined company will operate as Yarrow Bioscience, Inc. and trade under YARW.
• Initiation of a combined Phase 1b/2b trial for YB-101 in Graves disease in the first half of 2026.
• Expected Phase 1b data for YB-101 in Graves disease in the second half of 2027.
• Expected data from GenSci's Phase 1 TED trial in China in the first half of 2026.
• VYNE to declare and pay a cash dividend to pre-Merger VYNE stockholders.
• Certain executive officers and directors to be subject to a 180-day lock-up period post-closing.
• Parent to continue wind-down activities of Parent Legacy Business.

Key Dates

Recommendation

For existing VYNE shareholders, the transaction offers a cash dividend, providing some immediate value. However, the significant dilution to a 3% ownership stake and the complete pivot to a new, early-stage pipeline (YB-101) introduce substantial speculative risk. While YB-101 targets an unmet medical need and has secured significant funding, its clinical success is not guaranteed. A 'hold' recommendation allows investors to receive the dividend and observe the initial progress of the combined company's new strategic direction without committing further capital or exiting prematurely before the new pipeline's potential is clearer. The strategic shift and dilution make it a new investment thesis for existing VYNE holders.

Keywords

Merger, Biotechnology, Graves Disease, Thyroid Eye Disease, TSHR Antibody, YB-101, Clinical Stage, Autoimmune Disorders, Pharmaceutical, Nasdaq Listing, Private Placement, Drug Development